Xue Fengtian, Stoica Bogdan A, Hanscom Marie, Kabadi Shruti V, Faden Alan I
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, Maryland 21201, USA.
CNS Neurol Disord Drug Targets. 2014;13(4):558-66. doi: 10.2174/18715273113126660199.
Traumatic brain injury causes progressive neurodegeneration associated with chronic microglial activation. Recent studies show that neurodegeneration and neuroinflammation after traumatic brain injury can be inhibited as late as one month in animals by the activation of the metabotropic glutamate receptor 5 in microglia using (RS)-2-chloro-5- hydroxy-phenylglycine. However, the therapeutic potential of this agonist is limited due to its relatively weak potency and brain permeability. To address such concerns, we evaluated the anti-inflammatory activities of several positive allosteric modulators using various in vitro assays, and found that 3,3'-difluorobenzaldazine, 3-cyano-N-(1,3-diphenyl-1H-pyrazol- 5-yl)benzamide and 4-nitro-N-(1-(2-fluorophenyl)-3-phenyl-1H-pyrazol-5-yl)benzamide showed significantly improved potency which makes them potential lead compounds for further development of positive allosteric modulators for the treatment of traumatic brain injury.
创伤性脑损伤会导致与慢性小胶质细胞激活相关的进行性神经退行性变。最近的研究表明,在动物中,使用(RS)-2-氯-5-羟基苯甘氨酸激活小胶质细胞中的代谢型谷氨酸受体5,创伤性脑损伤后的神经退行性变和神经炎症可以在长达一个月的时间内得到抑制。然而,由于其相对较弱的效力和脑通透性,这种激动剂的治疗潜力有限。为了解决这些问题,我们使用各种体外试验评估了几种正变构调节剂的抗炎活性,发现3,3'-二氟苯甲醛嗪、3-氰基-N-(1,3-二苯基-1H-吡唑-5-基)苯甲酰胺和4-硝基-N-(1-(2-氟苯基)-3-苯基-1H-吡唑-5-基)苯甲酰胺显示出显著提高的效力,这使它们成为进一步开发用于治疗创伤性脑损伤的正变构调节剂的潜在先导化合物。